Ascendis Pharma’s FDA review of Achondroplasia drug gets 3-month delay
The FDA has classified recent submissions as a major amendment pushing the approval to its NDA for TransCon CNP back three months to February 28, 2026
The FDA has classified recent submissions as a major amendment pushing the approval to its NDA for TransCon CNP back three months to February 28, 2026
Abdomen-pelvis CT is the nation’s highest-volume CT category
The drug, intended for chronic weight management alongside diet and exercise, is now under the FDA’s new CNPV expedited review pathway
The approval by the US FDA comes after extensive safety testing and manufacturing improvements
The clearance for TELLTALE positions Transmural Systems at the forefront of next-generation electrosurgical solutions for structural heart interventions
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
The positive outcome clears the way for Glenmark to resume commercial manufacturing at the site
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
Subscribe To Our Newsletter & Stay Updated